A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma
Authors:
Open Access
- 7 April 2023
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (6) , 2577-2594
Abstract
Asthma affects 339 million people worldwide, with an estimated 5–10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produce clinically important adverse outcomes and increase the risk of mortality. Therefore, global guidelines recommend limiting the use of OCS. Despite the risks, research indicates that 40–60% of people with severe asthma are receiving or have received long-term OCS treatment. Although often perceived as a low-cost option, long-term OCS use can result in significant health impairments and costs owing to adverse outcomes and increased utilization of healthcare resources. Alternative treatment methods, such as biologics, may produce cost-saving benefits with a better safety profile. A comprehensive and concerted effort is necessary to tackle the continued reliance on OCS. Accordingly, a threshold for OCS use should be established to help identify patients at risk of OCS-related adverse outcomes. Receiving a total dose of more than 500 mg per year should trigger a review and specialist referral. Changes to national and local policies, following examples from other chronic diseases, will be crucial to achieving this goal. Globally, multiple barriers to change still exist, but specific steps have been identified to help clinicians reduce reliance on OCS. Implementing these changes will result in positive health outcomes for patients and social and economic benefits for societies.Keywords
Funding Information
- AstraZeneca
This publication has 68 references indexed in Scilit:
- Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional studynpj Primary Care Respiratory Medicine, 2015
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma RegistryThorax, 2014
- Glucocorticoid Dose Thresholds Associated With All‐Cause and Cardiovascular Mortality in Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Clinical, economic, and humanistic burden of asthma in Canada: a systematic reviewBMC Pulmonary Medicine, 2013
- Electronic health record-based assessment of oral corticosteroid use in a population of primary care patients with asthma: an observational studyAllergy, Asthma & Clinical Immunology, 2013
- Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapyPrimary Care Respiratory Journal, 2013
- The relationship between clinical outcomes and medication adherence in difficult-to-control asthma: Table 1Thorax, 2012
- Asthma outcomes workshop: OverviewJournal of Allergy and Clinical Immunology, 2012
- Adherence to MedicationNew England Journal of Medicine, 2005